Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $859000.0.

  • Ernexa Therapeutics' Accumulated Expenses fell 2632.93% to $859000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $859000.0, marking a year-over-year decrease of 2632.93%. This contributed to the annual value of $1.0 million for FY2024, which is 4680.4% down from last year.
  • As of Q3 2025, Ernexa Therapeutics' Accumulated Expenses stood at $859000.0, which was down 2632.93% from $938000.0 recorded in Q2 2025.
  • Over the past 5 years, Ernexa Therapeutics' Accumulated Expenses peaked at $5.0 million during Q3 2023, and registered a low of $859000.0 during Q3 2025.
  • Moreover, its 5-year median value for Accumulated Expenses was $2.0 million (2021), whereas its average is $2.2 million.
  • As far as peak fluctuations go, Ernexa Therapeutics' Accumulated Expenses soared by 38959.66% in 2021, and later plummeted by 7676.83% in 2024.
  • Ernexa Therapeutics' Accumulated Expenses (Quarter) stood at $2.1 million in 2021, then surged by 70.36% to $3.6 million in 2022, then tumbled by 47.79% to $1.9 million in 2023, then plummeted by 46.8% to $1.0 million in 2024, then dropped by 14.7% to $859000.0 in 2025.
  • Its last three reported values are $859000.0 in Q3 2025, $938000.0 for Q2 2025, and $1.4 million during Q1 2025.